News Website

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Adelaide Now

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis Adelaide Now

Published: May 18, 2026, 5:52 p.m.

Read Full Article

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.

Read Full Article

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.

Read Full Article

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Herald Sun

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis Herald Sun

Published: May 18, 2026, 3:08 p.m.

Read Full Article

Irwin family says Bindi is improving after missing gala - MSN

Irwin family says Bindi is improving after missing gala MSN

Published: May 18, 2026, 2:02 p.m.

Read Full Article

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology

Published: May 18, 2026, 1:33 p.m.

Read Full Article

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.

Read Full Article

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.

Read Full Article

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.

Read Full Article

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update BioSpace

Published: May 18, 2026, 1:17 a.m.

Read Full Article

Latest Articles

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Adelaide Now

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

Professor Avery’s AI research reveals 20% have undiagnosed endometriosis - Herald Sun

Irwin family says Bindi is improving after missing gala - MSN

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace

Subscribe to Our Newsletter